Overview

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-09-20

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Phase:

PHASE3

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

deucravacitinib